Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma

Presented by:
Philippe E. Spiess
Search for other papers by Philippe E. Spiess in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Peter A.S. Johnstone
Search for other papers by Peter A.S. Johnstone in
Current site
Google Scholar
PubMed
Close
 MD
, and
Eric Jonasch
Search for other papers by Eric Jonasch in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

At the NCCN 2023 Annual Conference, experts reviewed clinical data on established therapies for patients with metastatic renal cell carcinoma and discussed strategies to effectively manage both clear cell and non–clear cell tumor histologies in the setting of advanced stages. Depicted through 3 separate case studies, they strategized the selection of optimal first-line and subsequent-line therapies based on the individual case study and the tumor characteristics in each.

Disclosures: Dr. Jonasch has disclosed receiving consulting fees from Aravive, Inc., AVEO Pharmaceuticals, Inc., Calithera Biosciences, Eisai Inc., Exelixis Inc., Ipsen, Merck & Co., Inc., NiKang Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Takeda Pharmaceuticals North America, Inc.; and receiving grant/research support from Arrowhead Pharmaceuticals, Merck & Co., Inc., and NiKang Therapeutics, Inc. The remaining presenters have disclosed no relevant financial relationships.

Correspondence: Eric Jonasch, MD, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030. Email: ejonasch@mdanderson.org
  • Collapse
  • Expand
  • 1.

    Larcher A, Dell’Oglio P, Fossati N, et al. When to perform preoperative chest computed tomography for renal cancer staging. BJU Int 2017;120:490496.

  • 2.

    Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660673.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Borregales LD, Adibi M, Thomas AZ, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol 2016;8:130141.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:11331144.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2023. Accessed May 4, 2023. Available at: https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    McDermott DF, Lee JL, Bjarnason GA, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021;39:10201028.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hasanov E, Yeboa DN, Tucker MD, et al. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 2022;72:454489.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 941 697 8
PDF Downloads 424 206 7
EPUB Downloads 0 0 0